The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Agribusinesses and service providers: Increased reliance on big data may increase the power differential between agribusinesses/information service providers and farmers. If smallholders lack access to and/or control of their data, they may lose bargaining power vis-à-vis large value chain actors (like supermarkets) and data collectors.
=== Proteasomal chaperones === In addition to DUBs and Ligases, many other proteins associate with the proteasome and are important for degradation. These proteins typically consist of a Ubiquitin-like domain (UBL) and a Ubiquitin associating domain (UBA) with Dsk2, Rad23, and Ddi1 being classified as Proteasomal Chaperones. Dsk2 and Rad23 have UBLs that bind the receptors of the proteasome. Ddi1 has been shown to bind long K48-Ubiquitin chains and act as a protease and is probably not directly interacting with the proteasome.
ether A class of organic compounds and a functional group containing an oxygen atom connected to two alkyl or aryl groups, which may be the same or different. Ethers have the general formula R–O–R′, where R and R′ represent the alkyl or aryl groups.
The research reduces uncertainty by combining observational data with model projections, suggesting that stronger slowdown scenarios are more consistent with real-world conditions. Scientists warn that such a decline could have major impacts on global climate systems, including shifts in rainfall patterns, rising sea levels in the Atlantic, and extreme weather changes in Europe and other regions. 16 April – A study in the Journal of Geophysical Research: Planets presents "PlanetWaves", a model developed by researchers at MIT to predict wave formation under different planetary conditions. The results suggest that wave behaviour varies widely depending on gravity, atmosphere, and liquid composition, with gentle winds potentially generating large waves on Titan but only small ripples on denser or higher-gravity worlds. 17 April – A study in the Journal of Nutrition finds that egg consumption is associated with a lower risk of Alzheimer's Disease for those aged 65 and older. Eating one egg per day for at least five days a week reduces risk of Alzheimer's by up to 27%, researchers found. 21 April – The discovery of seven previously undetected organic molecules (trimethylbenzene, tetramethylbenzene, methyl benzoate, dihydronaphthalene, naphthalene, benzothiophene and methylnaphthalene) on Mars by the Curiosity rover is announced. 28 April – Astronomers using data from the Transiting Exoplanet Survey Satellite report 11,554 exoplanet candidates, including 10,091 new candidates, from a machine-learning-assisted search of 83.7 million stellar light curves.
Sources: en.wikipedia.org
=== Early research === The ability of palladium to absorb hydrogen was recognized as early as the nineteenth century by Thomas Graham. In the late 1920s, two Austrian-born scientists, Friedrich Paneth and Kurt Peters, originally reported the transformation of hydrogen into helium by nuclear catalysis when hydrogen was absorbed by finely divided palladium at room temperature. However, the authors later retracted that report, saying that the helium they measured was due to background from the air. In 1927, Swedish scientist John Tandberg reported that he had fused hydrogen into helium in an electrolytic cell with palladium electrodes. On the basis of his work, he applied for a Swedish patent for "a method to produce helium and useful reaction energy". Due to Paneth and Peters's retraction and his inability to explain the physical process, his patent application was denied. After deuterium was discovered in 1932, Tandberg continued his experiments with heavy water. The final experiments made by Tandberg with heavy water were similar to the original experiment by Fleischmann and Pons. Fleischmann and Pons were not aware of Tandberg's work. The term "cold fusion" was used as early as 1956 in an article in The New York Times about Luis Alvarez's work on muon-catalyzed fusion. Paul Palmer and then Steven Jones of Brigham Young University used the term "cold fusion" in 1986 in an investigation of "geo-fusion", the possible existence of fusion involving hydrogen isotopes in a planetary core.
=== Patenting === In the U.S., efforts into creating a chimeric entity appeared to be legal when the topic first came up. Developmental biologist Stuart Newman, a professor at New York Medical College in Valhalla, N.Y., applied for a patent on a human-animal chimera in 1997 as a challenge to the U.S. Patent and Trademark Office and the U.S. Congress, motivated by his moral and scientific opposition to the notion that living things can be patented at all. Prior legal precedent had established that genetically engineered entities, in general, could be patented, even if they were based on beings occurring in nature. After a seven-year process, Newman's patent finally received a flat rejection. The legal process had created a paper trail of arguments, giving Newman what he claimed was a victory. The Washington Post ran an article on the controversy that stated that it had raised "profound questions about the differences—and similarities—between humans and other animals, and the limits of treating animals as property."
Therefore, alterations in telomere length have great potential as a biomarker in cancer. Prostate cancer is the second most occurring cancer for men around the world today. 1 out of 8 men suffer from it every year. This diagnosis is an in vitro diagnostic test (IVD) that makes it possible to identify patients with a higher risk of suffering from aggressive prostate cancer. The prostate cancer diagnosis product, combined with the current screening method, can potentially prevent hundreds of prostate biopsies annually. Life Length has launched it on the market in 2022. It is a test that provides doctors with a useful and rapid tool for clinical decision-making. This test is a minimally invasive procedure that only requires a blood sample from the patient.
=== Software === SIP (software), a tool which generates C++ interface code for the programming language Python Scilab Image Processing, an image processing toolbox Soft Input Panel, on-screen input method for devices without standard keyboards Submission Information Packages, in the Open Archival Information System Reference Model; see Open Archival Information System#The OAIS environment and information model System Integrity Protection, a security feature of macOS by Apple, starting with OS X El Capitan
The equation displayed on the chart gives a means for calculating the absorbance and therefore concentration of the unknown samples. In Graph 1, x is concentration and y is absorbance, so one must rearrange the equation to solve for x and enter the absorbance of the measured unknown. It is likely that the unknown will have absorbance numbers outside the range of the standard. These should not be included calculations, as the equation given cannot apply to numbers outside of its limitations. In a large scale, one must compute the extinction coefficient using the Beer-Lambert Law A=εLC in which A is the measured absorbance, ε is the slope of the standard curve, L is the length of the cuvette, and C is the concentration being determined. In a micro scale, a cuvette may not be used and therefore one only has to rearrange to solve for x.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.